Company: DMAC
Filing Date: 2025-08-01
Form Type: S-3
Source: 0001437749-25-024290
Chunk: 11

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-01
Form: S-3
Chunk 11
---
2019 Omnibus Incentive Plan (2019 Plan), with a weighted average exercise price of $3.74 per share; |

| ● | 164,770 common shares reserved for issuance upon the settlement of deferred share units outstanding under the 2019 Plan; |

| ● | 7,607 common shares reserved for issuance upon the settlement of restricted share units outstanding under the 2019 Plan; |

| ● | 374,410 common shares reserved for issuance upon the exercise of outstanding stock options under the DiaMedica Therapeutics Inc. Stock Option Plan (Prior Plan), with a weighted average exercise price of $4.97 per share; |

| ● | 9,745 common shares reserved for issuance upon the settlement of deferred share units outstanding under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan (Prior DSU Plan); |

| ● | 590,000 common shares reserved for issuance upon the exercise of outstanding stock options under the DiaMedica Therapeutics Inc. 2021 Employment Inducement Plan (2021 Plan), with a weighted average exercise price of $2.53 per share; |

| ● | 754,919 common shares reserved for future issuance in connection with future grants under the 2019 Plan; and |

| ● | 357,500 common shares reserved for future issuance in connection with future grants under the 2021 Plan. |

<div align='center'>5

RISK FACTORS</div>

An investment in our common shares involves a high degree of risk. Before making an investment decision, you should carefully consider the following risks and the risks described in the“Risk Factors”section of our most recent Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 17, 2025 and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 13, 2025, as well as any amendment or update to our risk factors reflected in subsequent filings with the SEC. The occurrence of any of the events described below could have a material adverse effect on our business, financial condition, results of operations, cash flows, prospects or the value of our common shares. These risks are not the only ones that we face. Additional risks not currently known to us or that we currently deem immaterial also may impair our business. Please also read carefully the section below titled“Cautionary Note Regarding Forward-Looking Statements.”